| Bioactivity | NS3763 is a selective and noncompetitive GLUK5 receptor antagonist with an IC50 of 1.6 µM. NS3763 does not show significant antagonistic properties on GLUK6, AMPA or NMDA receptors[1]. |
| Target | IC50: 1.6 µM (GLUK5 receptor) |
| Invitro | In human embryonic kidney HEK293 cells expressing homomeric GLUK5 or GLUK6 receptors, NS3763 displays selectivity for inhibition of domoate-induced increase in intracellular calcium mediated through the GLUK5 subtype (IC50 = 1.6 µM) of kainate receptors compared with the GLUK6 subtype (IC50 > 30 µM)[1].NS3763 selectively inhibits l-glutamate- and domoate-evoked currents through GLUK5 receptors in HEK293 cells[1]. |
| Name | NS3763 |
| CAS | 70553-45-6 |
| Formula | C22H16N2O6 |
| Molar Mass | 404.37 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Jeppe K Christensen, et al. In vitro characterization of 5-carboxyl-2,4-di-benzamidobenzoic acid (NS3763), a noncompetitive antagonist of GLUK5 receptors. J Pharmacol Exp Ther. 2004 Jun;309(3):1003-10. |